Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer

This is a multicentre dose escalation and expansion, first‐in‐human study designed to evaluate the safety and tolerability of AZD9833, alone (Parts A and B), or in combination with palbociclib (Parts C and D), or in combination with everolimus (Parts E and F), or in combination with abemaciclib (± anastrozole) (Parts G and H), or in combination with capivasertib (Parts I and J), or in combination with ribociclib (± anastrozole) (Parts K and L), or in combination with anastrozole (Parts M and N) in women with endocrine‐resistant ER+ HER2‐ breast cancer that is not amenable to treatment with curative intent.